The 3 Best Brain-Computer Interface Stocks to Buy Now

Industry Overview - Brain-computer interfaces (BCI) have diverse applications across biotechnology, medical research, mental wellness, and gaming [1][4] - The U.S. population aged 65 and above reached 55.8 million as of the 2020 census, indicating a potential increase in the adoption of medical technology, including BCI [2] - The global BCI market is projected to grow at a compound annual growth rate (CAGR) of 17.5%, reaching a value of $6.2 billion by 2030, driven by new use cases [16] Company Analysis: Clearpoint Neuro Inc (CLPT) - Clearpoint Neuro has not been profitable in the past 12 months, yet its stock rose over 40% in July 2023 and has grown 16.87% over the last year, although it remains nearly 95% below its all-time high from 2012 [3][7] - The company has a market capitalization exceeding $200 million and collaborates with over 50 partners in biologics and drug delivery, positioning itself well in the emerging industry [7][8] Company Analysis: Snap Inc (SNAP) - Snap Inc is considered an unconventional player in the BCI space, with its stock down 80% from its post-pandemic high in September 2021, but recent upgrades from Morgan Stanley have increased price predictions from $12 to $15 due to improved ad performance [9][10] - The company's long-term sustainability is linked to strategic acquisitions, such as the purchase of NextMind, which specializes in BCI technology for virtual and augmented reality applications [11] Company Analysis: Integra Lifesciences (IART) - Integra Lifesciences has a long history in BCI technology, initially going public in 1995 and launching brain mapping software for Parkinson's Disease in 2007 [12][19] - The company has faced challenges in maintaining momentum post-pandemic, currently sitting over 50% below its highs, but announced plans for a new facility in Braintree, Massachusetts, expected to be operational by the first half of 2026 [13][19] - The State Board of Administration of Florida Retirement System increased its stake in Integra Lifesciences by 18.6%, raising its holdings to approximately $2,893,000 [13]